FDA Boss QUITS — Brutal War Exposed Inside Agency

FDA CHIEF QUITS

Dr. Marty Makary’s abrupt resignation as FDA Commissioner exposes the brutal clash between Trump’s reform zeal and the agency’s entrenched powers, leaving a $1.5 trillion industry in chaos.

Story Snapshot

Makary resigns after one year amid backlash from pro-life groups, vaping executives, pharma leaders, and White House allies.
Key failures: Mass layoffs eroded staff trust; deputy Vinay Prasad ousted twice over drugmaker conflicts.
Pro-life activists decried delays in restricting abortion pill mifepristone; vaping industry raged against blocked flavored product approvals.
Trump signaled Deputy Kyle Diamantas as acting commissioner; formal exit set for May 12, 2026.
Resignation highlights FDA bureaucracy’s resistance to outsider-led overhauls under Health Secretary Robert F. Kennedy Jr.

Makary’s Rapid Rise and Fall

Johns Hopkins surgeon Marty Makary gained fame criticizing COVID-19 lockdowns on Fox News. Trump appointed him FDA Commissioner in early 2025 to drain the agency’s swamp. Makary promised aggressive reforms targeting woke medicine and deep state inertia.

His outsider status fueled initial enthusiasm among conservatives but quickly sparked resistance from career bureaucrats and industry giants.

US FDA Commissioner Marty Makary resigned, President Trump said, after weeks of clashing with top White House and health advisers and drawing scrutiny for a series of controversial decisions, according to several people familiar with internal dynamics https://t.co/NumUuKkfFJ pic.twitter.com/HhmdfGW1J9

— Reuters Health (@Reuters_Health) May 12, 2026

Internal Chaos and Leadership Turmoil

Makary launched mass layoffs in 2025 to streamline operations, but these moves shattered staff morale. He handpicked oncologist Vinay Prasad as deputy, a podcaster critical of Big Pharma.

Prasad faced ouster twice—first over clashes with drugmakers, then rare disease advocates furious at perceived delays in specialty approvals. FDA insiders leaked accounts of overridden science, blaming Health Secretary Robert F. Kennedy Jr.’s influence.

Pro-Life Fury Over Mifepristone Delays

Pro-life groups, key to Trump’s GOP base, hammered Makary for stalling reviews of mifepristone, the abortion pill used in 95% of U.S. abortions. Approved in 2000, the drug faced post-Dobbs challenges, but Makary’s team moved too slowly for activists demanding swift restrictions. These post-Dobbs allies lobbied Trump directly, intensifying calls for Makary’s head as midterms loomed in November 2026.

Vaping Industry’s Desperate Lobby to Trump

Vaping executives from firms like Juul and Puff Bar bombarded Trump with complaints. Makary blocked flavored e-cigarette approvals, extending 2019-2020 crackdowns aimed at youth appeal. Industry leaders argued approvals ensured adult smokers’ switch from cigarettes, framing FDA as an existential threat to their $10 billion market. Trump, balancing coalitions, heard their pleas amid election pressures.

Sources are telling me @PatsyDiabetes is being considered as a possible replacement …. Marty Makary resigns as FDA commissioner following industry and White House backlash https://t.co/OyOiquTo64

— Hunter (@HuntersCoke) May 13, 2026

Pharma executives and rare disease organizations withheld support, decrying layoffs and Prasad’s policies as threats to R&D pipelines worth $100 billion annually. A White House official confirmed Makary’s exit on May 12, 2026. Trump publicly nodded to Deputy Kyle Diamantas as temporary replacement, signaling no tolerance for reform flops.

Consequences for FDA and Trump’s Agenda

Makary’s departure creates a leadership vacuum, delaying critical approvals and deepening staff distrust. Short-term, vaping firms face contraction; mifepristone battles escalate.

Long-term, persistent politicization risks eroding FDA credibility, though others see it as proof of swamp resistance. Trump’s team must now install a leader balancing allies without alienating base voters or igniting health crises.